Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder

OCD Clinical Trial

Official title:

Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03511534
• Other study ID #: 41165
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 23, 2017
• Est. completion date: June 2026

Study information

• Verified date: May 2024
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.

Description:

After completing one of the active clinical studies participants have the option to enroll in this protocol that offers open treatment.

The goal is to compare two forms of current standard treatments, psychotherapy vs pharmacotherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: June 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to speak and understand English

2. Capacity to consent (e.g. as determined by assessing the patient's understanding of the risks, benefits, and procedures of the study)

3. Completed an active study protocol at the Rodriguez Lab at Stanford University

Exclusion Criteria:

1. Children younger than 18

2. Active suicidality

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder
• OCD

Intervention

Behavioral:
• Psychotherapy
Evidenced based psychotherapy by a trained psychologist

Other:
• Pharmacotherapy
Pharmacotherapy by a psychiatrist

Locations

Country	Name	City	State
United States	Stanford University	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)	Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.	Up to 14 weeks